Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

Serum CD95L Level Correlates with Tumor Immune Infiltration and Is a Positive Prognostic Marker for Advanced High-Grade Serous Ovarian Cancer.

De La Motte Rouge T, Corné J, Cauchois A, Le Boulch M, Poupon C, Henno S, Rioux-Leclercq N, Le Pabic E, Laviolle B, Catros V, Levêque J, Fautrel A, Le Gallo M, Legembre P, Lavoué V.

Mol Cancer Res. 2019 Dec;17(12):2537-2548. doi: 10.1158/1541-7786.MCR-19-0449. Epub 2019 Sep 19.

PMID:
31537619
2.

[Next generation engineered T cells for cell therapy: from lymphoma to solid tumors].

Catros V.

Med Sci (Paris). 2019 Apr;35(4):316-326. doi: 10.1051/medsci/2019067. Epub 2019 Apr 30. French.

PMID:
31038109
3.

Phenotype of NK-Like CD8(+) T Cells with Innate Features in Humans and Their Relevance in Cancer Diseases.

Barbarin A, Cayssials E, Jacomet F, Nunez NG, Basbous S, Lefèvre L, Abdallah M, Piccirilli N, Morin B, Lavoue V, Catros V, Piaggio E, Herbelin A, Gombert JM.

Front Immunol. 2017 Mar 27;8:316. doi: 10.3389/fimmu.2017.00316. eCollection 2017.

4.

Metabolic Signature of Remote Ischemic Preconditioning Involving a Cocktail of Amino Acids and Biogenic Amines.

Chao de la Barca JM, Bakhta O, Kalakech H, Simard G, Tamareille S, Catros V, Callebert J, Gadras C, Tessier L, Reynier P, Prunier F, Mirebeau-Prunier D.

J Am Heart Assoc. 2016 Sep 24;5(9). pii: e003891.

5.

The ecto-ATPDase CD39 is involved in the acquisition of the immunoregulatory phenotype by M-CSF-macrophages and ovarian cancer tumor-associated macrophages: Regulatory role of IL-27.

d'Almeida SM, Kauffenstein G, Roy C, Basset L, Papargyris L, Henrion D, Catros V, Ifrah N, Descamps P, Croue A, Jeannin P, Grégoire M, Delneste Y, Tabiasco J.

Oncoimmunology. 2016 Apr 28;5(7):e1178025. doi: 10.1080/2162402X.2016.1178025. eCollection 2016 Jul.

6.

[Nectins and nectin-like receptors DNAM-1 and CRTAM: new ways for tumor escape].

Catros V, Dessarthe B, Thedrez A, Toutirais O.

Med Sci (Paris). 2014 May;30(5):537-43. doi: 10.1051/medsci/20143005017. Epub 2014 Jun 13. Review. French.

7.

Parallel FISH and immunohistochemical studies of ALK status in 3244 non-small-cell lung cancers reveal major discordances.

Cabillic F, Gros A, Dugay F, Begueret H, Mesturoux L, Chiforeanu DC, Dufrenot L, Jauffret V, Dachary D, Corre R, Lespagnol A, Soler G, Dagher J, Catros V, Le Calve M, Merlio JP, Belaud-Rotureau MA.

J Thorac Oncol. 2014 Mar;9(3):295-306. doi: 10.1097/JTO.0000000000000072.

8.

Involvement of purinergic receptors and NOD-like receptor-family protein 3-inflammasome pathway in the adenosine triphosphate-induced cytokine release from macrophages.

Gicquel T, Victoni T, Fautrel A, Robert S, Gleonnec F, Guezingar M, Couillin I, Catros V, Boichot E, Lagente V.

Clin Exp Pharmacol Physiol. 2014 Apr;41(4):279-86. doi: 10.1111/1440-1681.12214.

PMID:
24472059
9.

[Immunotherapy in epithelial ovarian carcinoma: hope and reality].

Lavoué V, Foucher F, Henno S, Bauville E, Catros V, Cabillic F, Levêque J.

J Gynecol Obstet Biol Reprod (Paris). 2014 Mar;43(3):198-210. doi: 10.1016/j.jgyn.2013.10.004. Epub 2013 Nov 11. Review. French.

10.

Repeated systemic administrations of both aminobisphosphonates and human Vγ9Vδ2 T cells efficiently control tumor development in vivo.

Santolaria T, Robard M, Léger A, Catros V, Bonneville M, Scotet E.

J Immunol. 2013 Aug 15;191(4):1993-2000. doi: 10.4049/jimmunol.1300255. Epub 2013 Jul 8.

11.

Immunity of human epithelial ovarian carcinoma: the paradigm of immune suppression in cancer.

Lavoué V, Thédrez A, Levêque J, Foucher F, Henno S, Jauffret V, Belaud-Rotureau MA, Catros V, Cabillic F.

J Transl Med. 2013 Jun 13;11:147. doi: 10.1186/1479-5876-11-147. Review.

12.

A quantitative deficiency in peripheral blood Vγ9Vδ2 cells is a negative prognostic biomarker in ovarian cancer patients.

Thedrez A, Lavoué V, Dessarthe B, Daniel P, Henno S, Jaffre I, Levêque J, Catros V, Cabillic F.

PLoS One. 2013 May 23;8(5):e63322. doi: 10.1371/journal.pone.0063322. Print 2013.

13.

CRTAM receptor engagement by Necl-2 on tumor cells triggers cell death of activated Vγ9Vδ2 T cells.

Dessarthe B, Thedrez A, Latouche JB, Cabillic F, Drouet A, Daniel P, de La Pintière CT, Catros V, Toutirais O.

J Immunol. 2013 May 1;190(9):4868-76. doi: 10.4049/jimmunol.1202596. Epub 2013 Mar 25.

14.

Sensitization of ovarian carcinoma cells with zoledronate restores the cytotoxic capacity of Vγ9Vδ2 T cells impaired by the prostaglandin E2 immunosuppressive factor: implications for immunotherapy.

Lavoué V, Cabillic F, Toutirais O, Thedrez A, Dessarthe B, de La Pintière CT, Daniel P, Foucher F, Bauville E, Henno S, Burtin F, Bansard JY, Levêque J, Catros V, Bouet-Toussaint F.

Int J Cancer. 2012 Aug 15;131(4):E449-62. doi: 10.1002/ijc.27353. Epub 2011 Dec 21.

15.

Aminobisphosphonate-pretreated dendritic cells trigger successful Vgamma9Vdelta2 T cell amplification for immunotherapy in advanced cancer patients.

Cabillic F, Toutirais O, Lavoué V, de La Pintière CT, Daniel P, Rioux-Leclerc N, Turlin B, Mönkkönen H, Mönkkönen J, Boudjema K, Catros V, Bouet-Toussaint F.

Cancer Immunol Immunother. 2010 Nov;59(11):1611-9. doi: 10.1007/s00262-010-0887-0. Epub 2010 Jun 26.

PMID:
20582413
16.

HLA-A*0201-restricted CEA-derived peptide CAP1 is not a suitable target for T-cell-based immunotherapy.

Fauquembergue E, Toutirais O, Tougeron D, Drouet A, Le Gallo M, Desille M, Cabillic F, de La Pintière CT, Iero M, Rivoltini L, Baert-Desurmont S, Leprince J, Vaudry H, Sesboué R, Frébourg T, Latouche JB, Catros V.

J Immunother. 2010 May;33(4):402-13. doi: 10.1097/CJI.0b013e3181d366da.

PMID:
20386466
17.

[Tgammadelta lymphocytes in oncology: unconventional killer lymphocytes].

Catros V, Toutirais O, Bouet F, Cabillic F, Desille M, Fournié JJ.

Med Sci (Paris). 2010 Feb;26(2):185-91. doi: 10.1051/medsci/2010262185. Review. French.

18.

DNAX accessory molecule-1 (CD226) promotes human hepatocellular carcinoma cell lysis by Vgamma9Vdelta2 T cells.

Toutirais O, Cabillic F, Le Friec G, Salot S, Loyer P, Le Gallo M, Desille M, de La Pintière CT, Daniel P, Bouet F, Catros V.

Eur J Immunol. 2009 May;39(5):1361-8. doi: 10.1002/eji.200838409.

19.

Increased frequency of nonconventional double positive CD4CD8 alphabeta T cells in human breast pleural effusions.

Desfrançois J, Derré L, Corvaisier M, Le Mével B, Catros V, Jotereau F, Gervois N.

Int J Cancer. 2009 Jul 15;125(2):374-80. doi: 10.1002/ijc.24366.

20.

Activation of tumor-specific T cells by dendritic cells expressing the NY-ESO-1 antigen after transfection with the cationic lipophosphoramide KLN5.

Le Gallo M, Toutirais O, Montier T, Cabillic F, Bouet F, Delépine P, Lehn P, Jotereau F, Catros V.

J Gene Med. 2008 Jun;10(6):628-36. doi: 10.1002/jgm.1188.

PMID:
18338820
21.

Vgamma9Vdelta2 T cell-mediated recognition of human solid tumors. Potential for immunotherapy of hepatocellular and colorectal carcinomas.

Bouet-Toussaint F, Cabillic F, Toutirais O, Le Gallo M, Thomas de la Pintière C, Daniel P, Genetet N, Meunier B, Dupont-Bierre E, Boudjema K, Catros V.

Cancer Immunol Immunother. 2008 Apr;57(4):531-9. Epub 2007 Sep 1.

PMID:
17764010
22.

[Immune anticancer response: recent advances in the treatment of renal cell carcinoma].

Bouet F, Catros V.

Ann Biol Clin (Paris). 2004 May-Jun;62(3):257-68. Review. French.

Supplemental Content

Loading ...
Support Center